Roche reports a strong start in 2019 and raises the outlook for the full-year
F. Hoffmann-La Roche Ltd / Roche reports a strong start in 2019 and raises the outlook for the full-year . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.
Basel, 17 April 2019
Group sales increase 8%1 at constant exchange rates and 9% in Swiss francs
Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq
Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor
Important approvals in the first quarter. In the US: Tecentriq combination therapy for extensive-stage small cell lung cancer; Tecentriq combination therapy for triple-negative breast cancer and companion diagnostic test; Herceptin Hylecta for subcutaneous injection for breast cancer; in the EU: Hemlibra for people with severe haemophilia A without factor VIII inhibitors; Tecentriq plus Avastin combination therapy for initial treatment of a form of lung cancer
Outlook raised for 2019 to mid-single digit sales growth
|Sales||CHF millions||As % of sales||% change|
|January - March 2019||2019||2018||2019||2018||At CER||In CHF|
|*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others|
Commenting on the Group's sales, Roche CEO Severin Schwan said: "We have started the year with strong sales growth, driven by the newly launched products in our Pharmaceuticals Division. Demand for our new medicines remains high. Health authorities granted a number of important approvals for our medicines in the first quarter. These include the first cancer immunotherapies for triple-negative breast cancer and small cell lung cancer, two diseases with high unmet patient need. Based on our performance in the first quarter, we raise the outlook for the full-year."